XXX XXXXX AND COMPANY. By: /s/ Xxxxx X. Xxxxxx --------------------------- Xxxxx X. Xxxxxx Vice President and Treasurer By: /s/ Xxxxxx X. Xxxxxxxxxx --------------------------- Xxxxxx X. Xxxxxxxxxx Secretary This is one of the Notes of the series designated herein issued under the Indenture described herein. CITIBANK, N.A., as Trustee By: /s/ Xxxxxx Xxxxxxxx --------------------------- Authorized Officer FORM OF REVERSE OF NOTE This Note is one of a duly authorized issue of a series of debt securities (the "Securities") of the Company, designated as its 6.77% Notes Due 2036 (the "Notes"). The Notes are limited to $300,000,000 aggregate principal amount and the Securities, including the Notes, are all issued or to be issued under and pursuant to the Indenture dated as of February 1, 1991 (herein called the "Indenture"), duly executed and delivered by the Company to Citibank, N.A., as Trustee (herein called the "Trustee"), to which Indenture and all Board Resolutions (as defined in the Indenture) as provided therein, reference is hereby made for a description of the rights, limitation of rights, obligations, duties and immunities thereunder of the Trustee, the Company and holders of the Notes. In case an Event of Default, as defined in the Indenture, shall have occurred and be continuing with respect to the Notes, the principal hereof may be declared, and upon such declaration shall become, due and payable, in the manner, with the effect and subject to the conditions provided in the Indenture. The Indenture provides that the holders of the majority in aggregate principal amount of the Notes at the time outstanding may on behalf of the holders of all of the Notes waive any past default under the Indenture and its consequences, except a default in the payment of the principal of or interest on any of the Notes, in the manner and to the extent provided in the Indenture. The Indenture contains provisions permitting the Company and the Trustee, with consent of the holders of not less than a majority of the aggregate principal amount of the Notes at the time outstanding, evidenced as in the Indenture provided, to execute supplemental indentures adding any provisions to or changing in any manner or eliminating any of the provisions of the Indenture or of any supplemental indenture with respect to the Notes, or modifying in any manner the rights of the holders of the Notes; provided, however, that no supplemental indenture shall (i) extend the maturity of any Note, or reduce the principal...
XXX XXXXX AND COMPANY. Applied Molecular Evolution, Inc ....
XXX XXXXX AND COMPANY. Immunocore Limited, having its principal place of business at 000 Xxxx Xxxxx, Xxxxxx Xxxx, Abingdon, Xxxx, XX00 0XX, Xxxxxx Xxxxxxx (“Immunocore”), and Xxx Xxxxx and Company, Lilly Xxxxxxxxx Xxxxxx, Xxxxxxxxxxxx, Xxxxxxx, 00000, Xxxxxx Xxxxxx of America (“Lilly”) entered into a Development and License Agreement On July 11, 2014 (“the Agreement”). The Parties desire to amend the Agreement to provide for transfer of Material and related confidential and proprietary information between the Parties. This is an Amendment to the Agreement, and this 3rd Amendment is entered into on the last date signed below by the Parties. The Parties are willing to provide each other with such Material and related confidential and proprietary information subject to the terms and conditions stated herein.
XXX XXXXX AND COMPANY. By: /s/ Xxxxxx X. Xxxx --------------------------------------------- Title: Executive Vice President, Science and Technology ----------------------------------------- STRUCTURAL GENOMIX, INC. By: /s/ M. Grey --------------------------------------------- Title: President and CEO ------------------------------------------
XXX XXXXX AND COMPANY. By: ------------------------ August X. Xxxxxxxx Executive Vice President VERTEX PHARMACEUTICALS INCORPORATED By: ------------------------- Xxxxxxx X. Xxxxxxx Senior Vice President and Chief Business Officer Schedule 1.32 to RESEARCH AND DEVELOPMENT AGREEMENT between VERTEX PHARMACEUTICALS INCORPORATED and XXX LILLY AND COMPANY LILLY PATENTS ------------------------------------------------------------------------------- U.S. Patents 4,569,794 Expires December 5, 2004 Title: Process for Purifying Proteins and Compounds Useful in such Process Research and Development Agreement -- Confidential -- Schedule 1.32 Schedule 1.84 to RESEARCH AND DEVELOPMENT AGREEMENT between VERTEX PHARMACEUTICALS INCORPORATED and XXX XXXXX AND COMPANY VERTEX PATENTS ------------------------------------------------------------------------------- HCV NS3 Serine Protease Inhibitor Program VERTEX PATENT APLICATIONS TITLE PATENT NUMBERS COUNTRIES INVENTORS Methods, Nucleotide 08/432,693 US (5/1/95) Su et al. Sequences and (US) Host Cells for PCT (5/1/96) Assaying WO Exogenous and 96/34 Endogenous 976 Protease Activity [*] Research and Development Agreement -- Confidential -- Schedule 1.84 Schedule 2.3(b) to RESEARCH AND DEVELOPMENT AGREEMENT between VERTEX PHARMACEUTICALS INCORPORATED and XXX LILLY AND COMPANY INITIAL MEMBERS OF RESEARCH TEAM ------------------------------------------------------------------------------ VERTEX Xx. Xxxxx Xxxx Dr. Xxxx Xxxxxxx Xx. Xxxxx Xxxx Xx. Xxxx Xxxxxx ONE TO BE DETERMINED Lilly Research Team Members: Xxxxxx X. Xxxxxxxx, Ph.D. HEAD, BIOLOGY FOR INFECTIOUS DISEASES RESEARCH Xxxxxx Xxxxx, Ph.D. RESEARCH FELLOW, VIROLOGY RESEARCH, INFECTIOUS DISEASES Xxxx X. Xxxxxx, Ph.D. HEAD OF CHEMISTRY AND BIOCHEMISTRY, INFECTIOUS DISEASES RESEARCH Xxxxxx X. Xxxxxxxx, M.D. DIRECTOR, INFECTIOUS DISEASES RESEARCH AND DECISION PHASE MEDICAL Research and Development Agreement -- Confidential -- Schedule 2.3(b) Schedule 3.3 to RESEARCH AND DEVELOPMENT AGREEMENT between VERTEX PHARMACEUTICALS INCORPORATED and XXX XXXXX AND COMPANY Hepatitis C Viris (HCV) [*] Inhibitor Program Vertex Research Activities: 1997-2000 -------------------------------------------------------------------------------- The accompanying list summarizes planned Vertex research activities for the design and development of novel, potent inhibitors of the Hepatitis C Virus (HCV) [*]. Changes to this schedule can and will be incorporated based on research findings published in the literature or from Vert...
XXX XXXXX AND COMPANY. By: /s/ Xxxxx X. Xxxxx
XXX XXXXX AND COMPANY. By: ----------------------------- Xxxxx X. Xxxxxx Vice President and Treasurer
XXX XXXXX AND COMPANY. GUILTY PLEA AGREEMENT
XXX XXXXX AND COMPANY. By: /s/ Xxxx Xxxxx By: /s/ Xxxx X. Lecheiter Name: Xxxx Xxxxx Name: Xxxx X. Lecheiter Title: Chairman Title: Exec. VP, Pharmaceutical Operations Date: December 17, 2004 Date: December 16, 2004 On behalf of Xxx Lilly and Company, Member By: /s/ Xxxx Xxxxx Name: Xxxx Xxxxx Title: President and CEO Date: December 17, 2004 On behalf of ICOS Corporation, Member
XXX XXXXX AND COMPANY. Signature
